AngioScore, a wholly-owned subsidiary of Spectranetics, has introduced the 200mm length AngioSculpt PTA scoring balloon catheters for the treatment of peripheral artery disease (PAD) above-the-knee.
AngioScore’s AngioSculpt PTA catheters gained the US Food and Drug Administration’s 510(k) approval for the dilatation of lesions in the iliac, femoral, iliofemoral, popliteal, infra-popliteal, and renal arteries, and to treat obstructive lesions of native or synthetic arteriovenous dialysis fistulae.
The AngioSculpt PTA scoring balloon catheters are not approved for use in the coronary or neuro-vasculature. They are anticipated to be particularly useful in treating the typical complex and long lesions found above-the-knee.
The AngioSculpt PTA catheters feature 200mm balloons in diameters of 4.0, 5.0 and 6.0mm with a scoring element specifically designed for these longer balloons.
MedStar Washington Hospital Center MedStar Heart Institute Peripheral Vascular Laboratory medical director Dr Nelson Bernardo said: "These new longer scoring balloons extend the capability of the AngioSculpt in treating the most challenging femoro-popliteal lesions safely and efficiently and will be a very important addition to the armamentarium of physicians treating complex endovascular disease."